**TTD: Annual General Mandate 2024**

On April 27, 2024, Tam Duc Cardiology hospital joint stock company announced General Mandate No. 01.2024/NQ-DHCD as follows:

Article I Approve the Performance Report 2023 and Audited Annual Financial Report 2023

In 2023, Tam Duc achieved the goal of treatment quality and patient satisfaction, with better operating capacity compared to in 2022.

On expertise: In 2023, medical examination activities increase by 3% compared to in 2022 (79,816/77,417). Inpatient treatment increases by 6% compared to in 2022 (4,671/4,417). Stable Surgical activities, 442 cases operated in 2023, equivalent to 2022 (442/443). Interventional cardiac catheterization is 7.7% higher than in 2022 (1,722/1,599). In terms of cardiac electrophysiology, 2023 increased by 4.5% compared to in 2022 (416/398). New techniques have been developed, ablation using 3D mapping to treat supraventricular tachycardia reduces X-ray exposure time, and the technique of placing a pacemaker from the HIS bundle reduces the long-term rate of heart failure, with good success. Paraclinical activities in 2023 decrease by 5% compared to in 2022 (969,659/1,019,186), but are higher than in pre-epidemic years.

About finance:

|  |  |  |
| --- | --- | --- |
|  | Plan in 2023 | Results in 2023 |
| Revenue: | VND 680 billion | VND 749.67 billion |
| Profit before tax: | VND 82 billion | VND 93.80 billion |
| Profit after tax: | VND 74 billion | VND 83.07 billion |

In 2023, Tam Duc recovers from the Covid 19 pandemic, operating capacity is better than in 2022. Therefore, financial results in 2023 exceed the plan.

Compared to the plan 2023, revenue increased by 10.2%

The profit before tax/Total revenue rate in 2023 is 12.51%.

Article II: Approve the report of the Supervisory Board in 2023

Article 3: Approve the Profit distribution plan for 2023. The Dividend payment level in 2023 is 33%/Face Value Instead Of 30% as The General Meeting of Shareholders 2023 On April 28, 2023 decided:

|  |  |
| --- | --- |
| 1. Profit after tax 2023 | 83,076,575,436 |
| 1. Appropriation for funds (General Mandate 01.2023/NQ-DHCD dated April 28, 2023) | 4,990,756,716 |
| * Board of Directors operating fund (3.6% Profit after Tax) | 2,990,756,716 |
| * Bonus and welfare fund  1. Remaining profit for dividends (3=1-2) | 2,000,000,000  78,085,818,720 |
| 1. Dividend payment - Expected 33% of par value | 54,022,736,000 |
| * Prepayment round 1 in August 2023: 10% | 16,370,526,000 |
| * Prepayment round 2 in January 2024: 10% | 16,370,526,000 |
| * 3rd installment payment (After approval by the Congress): 13% | 21,281,684,000 |
| 1. Remaining 2023 profit (5=3-4) | 24,063,082,720 |

Article IV: Approve proposal to authorize the Board of Directors to select an auditing company for the Financial Report 2024

The General Meeting of Shareholders authorized the Board of Directors to decide on the selection of an auditing company for the Financial Statements 2024.

Article V: Approve the Tam Duc plan in 2024:

On personnel: Tam Duc Cardiology hospital joint stock company has been operating stably and developing for 18 years. Tam Duc's leadership and expertise team has matured, but it is necessary to continue recruiting and providing postgraduate training in key technical positions such as emergency resuscitation, cardiac catheterization and prepare the succeeding leadership force.

On expertise: In 2024, medical examination, emergency care and inpatient treatment increase by 5% compared to in 2023. Heart surgery must reach over 400, interventional cardiac catheterization and cardiac electrophysiology must reach over 2,000.

About finance:

Total revenue: VND 700 billion

Profit before tax: VND 90 billion

Profit after tax: VND 82 billion

Dividends: 33%/par value

Article VI: Approve the appropriation for funds plan in 2024

Board of Directors' operating fund: 3.6%/ Profit after tax

Bonus and welfare fund: VND 3.5 billion

Article VII: Approve the dividend payment plan in 2024

Prepayment for the first round of dividends in 2024 at the rate of 10%/par value: August 2024

Prepayment for the second round of dividends in 2024 at the rate of 10%/par value: January 2025

Prepayment for the third round of dividends in 2024 at the rate of 13%/par value: After the General Meeting of Shareholder 2025

Article VIII: Approve the election of members for the Board of Directors for term VII of 2024-2028;

Election results:

|  |  |
| --- | --- |
| No. | Full name |
| 01 | Dr. Doctor. Nguyen Ngoc Chieu |
| 02 | Master. Doctor Phan Kim Phuong |
| 03 | Dr. Doctor Chu Trong Hiep |
| 04 | Master Pham Anh Dung |
| 05 | Doctor Pham Bich Xuan |

Based on the Rules for electing members of the Board of Directors, the Election Committee determined 5 candidates were elected to the Board of Directors for the term VII of 2024-2028.

The Board of Directors Term VII of 2024-2028 met for the first session on April 27, 2024 to elect Dr. Nguyen Ngoc Chieu as the Chair of the Board of Directors

Article IX: Approve the investment plan for coronary attachment and intervention system number 4 with a price at above and below VND 20 billion with a configuration suitable for professional requirements by Q4/2024, the method to be decided by the board of directors.

This General Mandate was read in front of the Meeting and approved by the Meeting at 11:10 a.m. on April 27, 2024.